loratadine has been researched along with Hay Fever in 220 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis." | 9.15 | Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. ( Chaker, AM; Dumitru, AF; Greve, J; Hess, L; Hindersin, S; Klenzner, T; Nebel, S; Scheckenbach, K; Schmidt-Weber, CB; Shamji, M; Wagenmann, M; Zahner, C; Zimmermann, C, 2011) |
| "These healthy adult volunteers with a history of seasonal allergic conjunctivitis had no clinical signs of ocular drying after 4 days of twice-daily treatment with topical epinastine." | 9.12 | An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. ( Ousler, GW; Torkildsen, GL; Workman, DA, 2007) |
| " In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma." | 9.11 | Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005) |
| "To evaluate the safety and efficacy of desloratadine 5 mg in patients experiencing moderate SAR, nasal congestion, and symptoms of seasonal allergic asthma." | 9.10 | Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. ( Berger, WE; Mansfield, LE; Schenkel, EJ, 2002) |
| "Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks." | 9.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <." | 9.10 | Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002) |
| "The possible effectiveness of loratadine in the treatment of allergic cough was assessed in 20 patients with allergic rhinoconjunctivitis and cough due to Parietaria judaica during the pollen season (April to July 1993)." | 9.08 | Loratadine in the treatment of cough associated with allergic rhinoconjunctivitis. ( Bianchi, B; Buscaglia, S; Canonica, GW; Catrullo, A; Ciprandi, G; Marchesi, E, 1995) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 9.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| " One hundred and seven hay fever patients, sensitive to birch pollen, were randomized into three parallel groups receiving loratadine 40 mg once daily, clemastine 1 mg twice daily, or placebo during the birch pollen season." | 9.06 | Treatment of hay fever with loratadine--a new non-sedating antihistamine. ( Irander, K; Odkvist, LM; Ohlander, B, 1990) |
| "In this double-blind study, 65 patients with hay fever were treated for 14 days with either loratadine 10 mg once daily, astemizole 10 mg once daily, or placebo." | 9.06 | Double-blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action. ( Oei, HD, 1988) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 8.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "Levocetirizine treatment induced significant symptom relief (P=0." | 6.71 | Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. ( Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2004) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 6.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| "When compared with desloratadine and placebo, Ze 339 shows better efficacy in relieving nasal obstruction symptoms and inhibiting critical components of the chemokine network and as such represents a novel symptomatic and possible prophylactic treatment for allergic rhinitis." | 5.15 | Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. ( Chaker, AM; Dumitru, AF; Greve, J; Hess, L; Hindersin, S; Klenzner, T; Nebel, S; Scheckenbach, K; Schmidt-Weber, CB; Shamji, M; Wagenmann, M; Zahner, C; Zimmermann, C, 2011) |
| "These healthy adult volunteers with a history of seasonal allergic conjunctivitis had no clinical signs of ocular drying after 4 days of twice-daily treatment with topical epinastine." | 5.12 | An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. ( Ousler, GW; Torkildsen, GL; Workman, DA, 2007) |
| " In this study we investigated the effect of treatment with desloratadine (DL) on systemic inflammation and on nasal and bronchial mucosal inflammation after nasal allergen provocation (NP) in subjects with grass-pollen-allergic rhinitis and asthma." | 5.11 | Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. ( Braunstahl, GJ; Fokkens, WJ; Hoogsteden, HC; Kleinjan, A; Overbeek, SE; Reinartz, SM; van Drunen, CM, 2005) |
| "To evaluate the safety and efficacy of desloratadine 5 mg in patients experiencing moderate SAR, nasal congestion, and symptoms of seasonal allergic asthma." | 5.10 | Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. ( Berger, WE; Mansfield, LE; Schenkel, EJ, 2002) |
| "Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks." | 5.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "Ketotifen fumarate is a topical antiallergic combination mast-cell stabilizer and antihistamine indicated for the temporary prevention of ocular itching due to allergic conjunctivitis." | 5.10 | Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo ( Crampton, HJ, 2003) |
| "In a double-blind, randomized study 62 patients with grass pollen-induced allergic rhinitis received a nasal glucocorticoid (fluticasone propionate aqueous nasal spray [FPANS], 200 microg/d), an antileukotriene (montelukast, 10 mg/d), a combination of montelukast with an antihistamine (loratadine, 10 mg/d), or placebo throughout the season." | 5.10 | Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. ( Lötvall, J; Praks, L; Pullerits, T; Ristioja, V, 2002) |
| "Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <." | 5.10 | Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002) |
| "The possible effectiveness of loratadine in the treatment of allergic cough was assessed in 20 patients with allergic rhinoconjunctivitis and cough due to Parietaria judaica during the pollen season (April to July 1993)." | 5.08 | Loratadine in the treatment of cough associated with allergic rhinoconjunctivitis. ( Bianchi, B; Buscaglia, S; Canonica, GW; Catrullo, A; Ciprandi, G; Marchesi, E, 1995) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 5.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| " One hundred and seven hay fever patients, sensitive to birch pollen, were randomized into three parallel groups receiving loratadine 40 mg once daily, clemastine 1 mg twice daily, or placebo during the birch pollen season." | 5.06 | Treatment of hay fever with loratadine--a new non-sedating antihistamine. ( Irander, K; Odkvist, LM; Ohlander, B, 1990) |
| "The efficacy and safety of loratadine, 40 mg once daily, were compared with terfenadine, 60 mg twice daily, and placebo in controlling symptoms of ragweed hay fever." | 5.06 | Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis. ( Bedard, P; Del Carpio, J; Gutkowski, A; Hebert, J; Prevost, M; Schulz, J; Turenne, Y; Yeadon, C, 1988) |
| "In this double-blind study, 65 patients with hay fever were treated for 14 days with either loratadine 10 mg once daily, astemizole 10 mg once daily, or placebo." | 5.06 | Double-blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action. ( Oei, HD, 1988) |
| " Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0." | 4.86 | Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010) |
| "Desloratadine is approved for the treatment of symptoms associated with seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in patients aged > or =12 years." | 4.82 | Desloratadine: a nonsedating antihistamine. ( Kockler, DR; Limon, L, 2003) |
| "Levocetirizine and desloratadine are newer antihistamines indicated for the treatment of allergic rhinitis and chronic idiopathic urticaria." | 4.82 | A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis. ( Canonica, GW; Passalacqua, G, 2005) |
| "Our purpose in this study was to test whether an H1 receptor antagonist, desloratadine, could reduce the augmented effect of an ongoing allergic reaction on acute bacterial rhinosinusitis." | 3.72 | Desloratadine partially inhibits the augmented bacterial responses in the sinuses of allergic and infected mice. ( Blair, C; Kirtsreesakul, V; Naclerio, RM; Thompson, K; Yu, X, 2004) |
| "Cetirizine 10 mg was statistically significantly more efficacious than placebo in the treatment of SAR symptoms in children ages 6-11 years." | 2.84 | Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. ( Berger, WE; Franklin, KB; LaForce, CF; Nayak, AS; Patel, MK; Urdaneta, ER; Wu, MM, 2017) |
| "Bilastine is a novel, nonsedating H(1)-antihistamine developed for symptomatic treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria." | 2.74 | Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. ( Bachert, C; Dimitrov, V; Gorina, MM; Ivan, P; Kuna, P; Loureiro, A; Sanquer, F; van de Heyning, P, 2009) |
| "Desloratadine was significantly more effective than placebo in preventing post-challenge ocular pruritus (P<0." | 2.74 | Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms. ( Gomes, P; Gopalan, G; Srinivasan, S; Torkildsen, GL; Welch, D, 2009) |
| "Loratadine-montelukast was more effective than placebo (P < or = ." | 2.74 | Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. ( Briscoe, MP; Danzig, M; Day, JH; Ratz, JD; Yao, R, 2009) |
| "Desloratadine was effective and safe." | 2.74 | Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. ( Bachert, C; Bindslev Jensen, C; Bousquet, J; Canonica, GW; Fokkens, WJ; Keith, P; Lorber, R; Mullol, J; Ring, J; Van Cauwenberge, P; Zuberbier, T, 2009) |
| " The incidence of side effect of treatment group was 2." | 2.73 | [The investigation of efficacy and safety of Aerius to seasonal allergic rhinitis]. ( Cui, Y; Gao, Q; Liu, Z; Xu, K; You, X, 2008) |
| "Desloratadine is a potent antihistamine." | 2.73 | The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. ( Adalioglu, G; Dizdar, EA; Dogan, C; Kalayci, O; Keskin, O; Sekerel, BE; Tuncer, A, 2007) |
| "Desloratadine was well tolerated, with an AE rate similar to placebo." | 2.73 | Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. ( Devillier, P; Dreyfus, I; Neukirch, C; Pradalier, A, 2007) |
| "Both mometasone furoate NS treatment regimens were more effective than loratadine or placebo for TNSS (P < ." | 2.73 | Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. ( Anolik, R, 2008) |
| "Desloratadine was significantly better than placebo (p < 0." | 2.72 | Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. ( Horak, F; Kavina, A; Marschall, K; Munzel, U; Petzold, U; Zieglmayer, R; Zieglmayer, UP, 2006) |
| "Desloratadine treatment for 14 days improved nasal airflow and resistance as well as symptom and QOL scores in patients with symptomatic SAR during the allergy season." | 2.72 | Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. ( Harris, AG; Iezzoni, D; Jalowayski, AA; Meltzer, EO; Vogt, K, 2006) |
"Desloratadine was significantly superior to placebo in maintaining nasal airflow (P | 2.71 | Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. ( Harris, AG; Horak, F; Stübner, P; Zieglmeyer, R, 2003) | |
| "Montelukast is a leukotriene receptor antagonist recently approved for the treatment of seasonal allergic rhinitis (SAR)." | 2.71 | Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. ( Arastu, R; Baidoo, CA; Faris, MA; Howland, WC; Klein, KC; Philpot, EE; Ratner, PH; Rickard, KA, 2003) |
| "Desloratadine tablet was administered in 5 mg doses." | 2.71 | [Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis]. ( Farkas, H, 2003) |
| "Azelastine nasal spray is an effective treatment for patients with seasonal allergic rhinitis who do not respond to loratadine and is an alternative to switching to another oral antihistamine or to using multiple antihistamines." | 2.71 | Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. ( Berger, WE; White, MV, 2003) |
| "Montelukast was more effective than placebo in improving scores for the primary endpoint of daytime nasal symptoms (P = 0." | 2.71 | Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. ( Meltzer, EO; Menten, J; Pedinoff, AJ; Philip, G; Ratner, PH; Reiss, TF; van Adelsberg, J, 2003) |
| " Overall, all treatments were safe and well tolerated." | 2.71 | Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. ( Hampel, F; Howland, W; Ratner, P; Van Bavel, J, 2004) |
| " All treatments were well tolerated and no serious adverse events were recorded." | 2.71 | A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. ( Dumur, JP; Izquierdo, I; Pérez, I; Saint-Martin, F, 2004) |
| "Both ebastine 20 and 10 mg were well tolerated and proved safe in the treatment of SAR." | 2.71 | A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. ( Hampel, F; Howland, W; Ratner, P; Van Bavel, J, 2004) |
| "Levocetirizine treatment induced significant symptom relief (P=0." | 2.71 | Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. ( Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2004) |
| " Desloratadine, an oral non-sedating antihistamine, has been shown in multiple studies to be safe and effective in relieving the symptoms of AR and chronic idiopathic urticaria (CIU) in adults and adolescents." | 2.71 | Safety of desloratadine syrup in children. ( Bloom, M; Herron, J; Staudinger, H, 2004) |
| " No unusual or unexpected adverse events were reported." | 2.71 | Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. ( Grubbe, R; Lutsky, B; Pleskow, W; Weiss, S, 2005) |
| "Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period." | 2.71 | The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. ( Fujieda, S; Hyo, S; Kawada, R; Kitazawa, S; Takenaka, H, 2005) |
| "Desloratadine 5-20 mg was significantly (P <." | 2.70 | 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. ( Lorber, R; Salmun, LM, 2002) |
| "Loratadine was significantly superior to placebo in 3 of 10 trials (30%), consistent with rates found in 3 pivotal group trials used for FDA approval (24%, 17%, and 0%)." | 2.70 | Single-patient drug trial methodology for allergic rhinitis. ( Del Rio, E; Rebell, G; Reitberg, DP; Weiss, SL; Zaias, N, 2002) |
| "The objective of the study was to evaluate the adverse reactions of Loratadine plus Pseudoephedrine Sulfate Repetabs Tables (LTD+PSE Repetabs) (Loratadine 5 mg + Pseudoephedrine 120 mg) twice daily with that of loratadine (5 mg) twice daily and pseudoephedrine (60 mg) quarter daily in the treatment of patients with allergic rhinitis." | 2.70 | A comparative study of the side effects between pseudoephedrine in Loratadine plus Pseudoephedrine Sulfate Repetabs Tables and loratadine + pseudoephedrine tablet in treatment of allergic rhinitis in Thai patients. ( Chochaipanichnon, L; Kerekhanjanarong, V; Saengpanich, S; Supiyaphun, P, 2002) |
| "Desloratadine (5 mg) was administered orally once daily for 5 days in a placebo-controlled, crossover design to 24 patients with allergic rhinitis." | 2.70 | Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. ( Andersson, M; Greiff, L; Persson, CG, 2002) |
| "Desloratadine is a new treatment option for patients with IAR and nasal congestion." | 2.70 | Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. ( Nayak, AS; Schenkel, E, 2001) |
| "Montelukast alone or in combination with loratadine is well tolerated and provides clinical and quality-of-life benefits for patients with seasonal allergic rhinitis." | 2.70 | Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. ( Lu, S; Malice, MP; Nayak, AS; Philip, G; Reiss, TF, 2002) |
| "Cetirizine is a newer once-daily selective H1-antagonist." | 2.69 | Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. ( Briscoe, M; Day, JH; Widlitz, MD, 1998) |
| "The histamine covariant was more important in the allergen effect of astemizole than in that of loratadine." | 2.69 | Changes in skin-test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis. ( Bousquet, J; Cougnard, J; Czarlewski, W; Danzig, M; Michel, FB, 1998) |
| "Loratadine was not statistically different from placebo in clinician and patient symptom score ratings nor in overall clinician and patient evaluations." | 2.69 | A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. ( Bowers, BW; Cook, CK; Hampel, FC; Howland, WC; Martin, BG; Ratner, PH; Rogenes, PR; van Bavel, JH; Westlund, RE, 1998) |
| " Twenty-four hours after intake, the dose-response curve of nasal obstruction to histamine was significantly lower after treatment with cetirizine compared with placebo (P < 0." | 2.69 | Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. ( Benabdesselam, O; Frossard, N; Glasser, N; Lacronique, J; Melac, M; Pauli, G, 1998) |
| "Cetirizine was more effective on histamine skin test responses." | 2.69 | Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. ( Bousquet, J; Demoly, P; Harris, AG; Michel, FB; Persi, L; Tisserand, B, 1999) |
| "Azelastine hydrochloride is an H1-receptor antagonist with antiinflammatory properties that is available in the US as Astelin Nasal Spray for the treatment of seasonal allergic rhinitis." | 2.69 | Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. ( Berger, WE; Fineman, SM; Lieberman, P; Miles, RM, 1999) |
| "Triamcinolone acetonide aqueous was significantly (P < ." | 2.69 | Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. ( Condemi, J; Lim, J; Schulz, R, 2000) |
| "Fexofenadine HCl was also significantly better than loratadine (P | 2.69 | Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. ( Juniper, EF; Van Cauwenberge, P, 2000) |
| " Somnolence scores were similar for both groups at baseline and at the time of dosing (8:00 AM)." | 2.69 | Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. ( Gates, D; Greiding, L; Heithoff, K; Ramon, F; Salmun, LM; Scharf, M, 2000) |
| "Loratadine was well tolerated in this small, selected group of children aged 2 to 5 years at a dose providing exposure similar to that with the adult dose (ie, 10 mg once daily)." | 2.69 | The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ( Affrime, MB; Banfield, C; Herron, JM; Lorber, R; Padhi, D; Salmun, LM, 2000) |
| " All treatments were generally well tolerated with no serious or unusual adverse events." | 2.68 | Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. ( Boggs, P; Bronsky, E; Findlay, S; Gawchik, S; Georgitis, J; Mansmann, H; Meltzer, E; Morris, R; Sholler, L; Wolfe, J, 1995) |
| " Major and total symptom complex scores, global efficacy and overall satisfaction, and adverse events were assessed." | 2.68 | Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. ( Meltzer, EO; Weiler, JM; Widlitz, MD, 1996) |
| "Pretreatment with loratadine seems to reduce both the number and severity of systemic reactions in specific cluster immunotherapy." | 2.68 | Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. ( Johnsen, CR; Malling, HJ; Mosbech, H; Nielsen, L; Poulsen, LK, 1996) |
| "Mometasone furoate and BDP were equally well tolerated." | 2.68 | Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. ( Hebert, JR; Lutsky, BN; Nolop, K, 1996) |
| " In conclusion, this study found cetirizine and loratadine to have similar nasal efficacy at therapeutic dosage 4 h after intake, whereas cetirizine was more effective than loratadine 1." | 2.68 | Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. ( Benabdesselam, O; Braun, JJ; Frossard, N; Glasser, N; Lacronique, J; Melac, M; Pauli, G, 1997) |
| " Both were dosed at 10 mg/day." | 2.68 | Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. ( Canonica, GW; Ciprandi, G; Danzig, M; Passalacqua, G; Pronzato, C; Ricca, V, 1997) |
| "05) for controlling nasal symptoms and safe in terms of short term biochemical and haematological changes and adverse effects noted." | 2.67 | Efficacy and safety of loratadine compared with astemizole in Malaysian patients with allergic rhinitis. ( Amin, MJ; Lee, ST, 1994) |
| "Astemizole-treated patients showed statistically significantly more weight gain than did loratadine-treated patients." | 2.67 | Once daily loratadine versus astemizole once daily. ( Banov, C; Boggs, P; Chervinsky, P; Georgitis, J; Greenstein, S; Vande Souwe, R, 1994) |
| "Terfenadine was more effective than both loratadine (P less than ." | 2.67 | Suppression of epicutaneous reactivity by terfenadine and loratadine. ( Small, P, 1992) |
| "In a three-way, double-blind, crossover study the onset of action and effects at the end of the dosing interval of 10 mg/day astemizole, 10 mg/day loratadine and 120 mg/day terfenadine forte given for 3 days to six atopic volunteers were assessed using the Vienna challenge chamber (VCC)." | 2.67 | Onset and duration of the effects of three antihistamines in current use--astemizole, loratadine and terfenadine forte--studied during prolonged, controlled allergen challenges in volunteers. ( Berger, U; Horak, F; Jäger, S, 1992) |
| " Recommended dosage of loratadine (CAS 79794-75-5) is 10 mg once daily, whereas terfenadine (CAS 50679-08-8) until recently has been recommended as 60 mg twice daily." | 2.67 | Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow. ( Hindberg Rasmussen, W; Høi, L; Lorentzen, KA; Nüchel Petersen, L; Olsen, OT; Svendsen, UG, 1992) |
| "Thus loratadine is an effective and safe antihistamine when given once daily for the symptomatic relief of seasonal allergic rhinitis." | 2.67 | Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. ( Katelaris, C, 1990) |
| "Loratadine appears to be a simple, effective and safe therapy for seasonal allergic rhinitis." | 2.66 | Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. ( Andreoli, A; Boner, AL; Marchesi, E; Miglioranzi, P; Richelli, C, 1989) |
| "Loratadine was particularly effective compared with placebo in relieving nasal discharge, sneezing, and itching/burning eyes." | 2.66 | Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. ( Bedard, PM; Del Carpio, J; Gutkowski, A; Hebert, J; Kabbash, L; Nedilski, M; Prevost, M; Schulz, J; Turenne, Y, 1989) |
| "Loratadine was found to be both safe and efficacious." | 2.66 | Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. ( Bergner, A; Connell, JT; Dockhorn, RJ; Falliers, CJ; Grabiec, SV; Shellenberger, MK; Weiler, JM, 1987) |
| "Loratadine is a long-acting H1 antagonist devoid of anticholinergic and sedative effects." | 2.66 | Double-blind placebo-controlled study of loratadine, mequitazine, and placebo in the symptomatic treatment of seasonal allergic rhinitis. ( Bousquet, J; Lherminier, M; Michel, FB; Montes, F; Schwab, D; Skassa-Brociek, W; Verdier, M, 1988) |
| " Mean reductions in nasal congestion scores were comparable between the once- and twice-daily dosing regimens of the combination drug." | 2.45 | Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion. ( Anolik, R, 2009) |
| "Fexofenadine was associated with significantly lower nasal congestion scores compared with placebo in 4 studies (P <- 0." | 2.45 | A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. ( Bachert, C, 2009) |
| "Desloratadine has been approved by the European Medicines Evaluation Agency for the treatment of intermittent and persistent AR, as defined by the ARIA classification." | 2.44 | Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. ( Bachert, C; van Cauwenberge, P, 2007) |
| " No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules." | 2.44 | Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. ( Devillier, P; Faisy, C; Roche, N, 2008) |
| "Histamine is a key mediator of the allergic immediate reaction." | 2.43 | [Oral second generation antihistamines in allergic rhinitis]. ( Riechelmann, H, 2005) |
| "Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist." | 2.43 | Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. ( DuBuske, LM, 2005) |
| " Although first-generation antihistamines can cause sedation and cognitive impairment, second-generation antihistamines are relatively non-sedating and free of such adverse events owing to their comparative inability to penetrate the blood-brain barrier." | 2.43 | The safety and efficacy of desloratadine for the management of allergic disease. ( Berger, WE, 2005) |
| "Desloratadine is a once-daily oral antihistamine with a favourable sedation profile that is approved for the treatment of AR and CIU." | 2.43 | Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. ( Gupta, S; Kantesaria, B; Khalilieh, S; Kim, K; Lorber, R; Lutsky, B; Manitpisitkul, P; Prenner, B; Wang, Z, 2006) |
| "Desloratadine was used as a probe to further elucidate the mechanisms involved during an allergic response." | 2.42 | Anti-inflammatory properties of desloratadine. ( Agrawal, DK, 2004) |
| "Desloratadine treatment was associated with less deterioration from baseline in the mean nasal airflow (P < 0." | 2.41 | Impact and modulation of nasal obstruction. ( Horak, F, 2002) |
| "Triamcinolone is a commonly used synthetic corticosteroid that has recently been tested in a large clinical trial for chronic obstructive pulmonary disease and shown to have some benefits." | 2.41 | Triamcinolone: new and old indications. ( Doggrell, SA, 2001) |
| "In this review of the current treatment of seasonal allergic rhinitis, the clinical studies that compare these four new second-generation H1-receptor antagonists are discussed." | 2.38 | H1-receptor antagonist treatment of seasonal allergic rhinitis. ( Kaiser, HB, 1990) |
| "Loratadine is a long acting antihistamine which has a high selectivity for peripheral histamine H1-receptors and lacks the central nervous system depressant effects often associated with some of the older antihistamines." | 2.38 | Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. ( Clissold, SP; Goa, KL; Sorkin, EM, 1989) |
| "Treatment with desloratadine dominated placebo (cost less and resulted in greater effectiveness) for all measures of effectiveness." | 1.36 | The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis. ( Lorber, R; Navaratnam, P; Shekar, T; Sullivan, PW, 2010) |
| " Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population." | 1.35 | Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. ( Moeller, ML; Nahata, MC; Phan, H, 2009) |
| "Desloratadine is a new, selective, H(1)-receptor antagonist that also has anti-inflammatory activity." | 1.31 | Desloratadine: A new, nonsedating, oral antihistamine. ( Geha, RS; Meltzer, EO, 2001) |
| "Desloratadine was well tolerated in clinical trials and had an adverse event profile similar to that of placebo in patients with SAR (with or without asthma) or CIU." | 1.31 | Desloratadine. ( Jarvis, B; McClellan, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (5.91) | 18.7374 |
| 1990's | 54 (24.55) | 18.2507 |
| 2000's | 134 (60.91) | 29.6817 |
| 2010's | 19 (8.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yonekura, S | 1 |
| Okamoto, Y | 1 |
| Sakurai, D | 1 |
| Iinuma, T | 1 |
| Sakurai, T | 1 |
| Yoneda, R | 1 |
| Kurita, J | 1 |
| Hanazawa, T | 1 |
| Kawasaki, Y | 1 |
| Nayak, AS | 3 |
| Berger, WE | 6 |
| LaForce, CF | 1 |
| Urdaneta, ER | 1 |
| Patel, MK | 1 |
| Franklin, KB | 1 |
| Wu, MM | 2 |
| Liu, Y | 2 |
| Ye, XJ | 1 |
| Zhao, CL | 1 |
| Ji, Q | 1 |
| Imoto, Y | 1 |
| Takabayashi, T | 1 |
| Sakashita, M | 1 |
| Tokunaga, T | 1 |
| Morikawa, T | 1 |
| Ninomiya, T | 1 |
| Okamoto, M | 1 |
| Narita, N | 1 |
| Fujieda, S | 2 |
| Ozturk, AB | 1 |
| Celebioglu, E | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| Xiong, M | 1 |
| Fu, X | 1 |
| Deng, W | 1 |
| Lai, H | 1 |
| Yang, C | 1 |
| Costa, DJ | 1 |
| Marteau, P | 1 |
| Amouyal, M | 1 |
| Poulsen, LK | 2 |
| Hamelmann, E | 1 |
| Cazaubiel, M | 1 |
| Housez, B | 1 |
| Leuillet, S | 1 |
| Stavnsbjerg, M | 1 |
| Molimard, P | 1 |
| Courau, S | 1 |
| Bousquet, J | 8 |
| Lu, Y | 1 |
| Yin, M | 1 |
| Cheng, L | 2 |
| Durham, SR | 2 |
| Creticos, PS | 1 |
| Nelson, HS | 1 |
| Li, Z | 1 |
| Kaur, A | 1 |
| Meltzer, EO | 8 |
| Nolte, H | 2 |
| You, X | 1 |
| Liu, Z | 1 |
| Xu, K | 1 |
| Gao, Q | 1 |
| Cui, Y | 1 |
| Corren, J | 2 |
| Lemay, M | 1 |
| Lin, Y | 1 |
| Rozga, L | 1 |
| Randolph, RK | 1 |
| Li, Y | 1 |
| Liu, F | 1 |
| Ciebiada, M | 1 |
| Ciebiada, MG | 1 |
| Kmiecik, T | 1 |
| DuBuske, LM | 3 |
| Gorski, P | 2 |
| Bachert, C | 7 |
| Kuna, P | 3 |
| Sanquer, F | 1 |
| Ivan, P | 1 |
| Dimitrov, V | 1 |
| Gorina, MM | 1 |
| van de Heyning, P | 1 |
| Loureiro, A | 1 |
| Torkildsen, GL | 2 |
| Gomes, P | 1 |
| Welch, D | 1 |
| Gopalan, G | 2 |
| Srinivasan, S | 1 |
| Day, JH | 7 |
| Briscoe, MP | 5 |
| Ratz, JD | 2 |
| Danzig, M | 5 |
| Yao, R | 1 |
| Luo, H | 1 |
| Tao, Z | 1 |
| Yan, N | 1 |
| Liang, J | 1 |
| Wang, P | 1 |
| Wang, J | 1 |
| Anolik, R | 3 |
| Grubbe, RE | 1 |
| Lumry, WR | 1 |
| Canonica, GW | 8 |
| Mullol, J | 2 |
| Van Cauwenberge, P | 5 |
| Bindslev Jensen, C | 1 |
| Fokkens, WJ | 3 |
| Ring, J | 2 |
| Keith, P | 2 |
| Lorber, R | 7 |
| Zuberbier, T | 2 |
| Demoly, P | 2 |
| Dreyfus, I | 2 |
| Dhivert-Donnadieu, H | 1 |
| Mesbah, K | 1 |
| Lu, S | 3 |
| Malice, MP | 2 |
| Dass, SB | 1 |
| Reiss, TF | 4 |
| Phan, H | 1 |
| Moeller, ML | 1 |
| Nahata, MC | 1 |
| Maurer, M | 1 |
| Sullivan, PW | 1 |
| Navaratnam, P | 1 |
| Shekar, T | 1 |
| Horak, F | 8 |
| Zieglmayer, P | 1 |
| Zieglmayer, R | 4 |
| Lemell, P | 1 |
| Jensen, CB | 1 |
| Dumitru, AF | 1 |
| Shamji, M | 1 |
| Wagenmann, M | 1 |
| Hindersin, S | 1 |
| Scheckenbach, K | 1 |
| Greve, J | 1 |
| Klenzner, T | 1 |
| Hess, L | 1 |
| Nebel, S | 1 |
| Zimmermann, C | 1 |
| Zahner, C | 1 |
| Schmidt-Weber, CB | 1 |
| Chaker, AM | 1 |
| Johnson, VV | 1 |
| Mösges, R | 1 |
| König, V | 1 |
| Köberlein, J | 1 |
| Stephan, F | 1 |
| Maatouk, I | 1 |
| Moutran, R | 1 |
| Obeid, G | 1 |
| Karaki, M | 1 |
| Akiyama, K | 1 |
| Mori, N | 1 |
| Salmun, LM | 3 |
| Reitberg, DP | 1 |
| Del Rio, E | 1 |
| Weiss, SL | 1 |
| Rebell, G | 1 |
| Zaias, N | 1 |
| Supiyaphun, P | 1 |
| Chochaipanichnon, L | 1 |
| Kerekhanjanarong, V | 1 |
| Saengpanich, S | 2 |
| Wilson, AM | 2 |
| Haggart, K | 2 |
| Sims, EJ | 2 |
| Lipworth, BJ | 4 |
| Greiff, L | 2 |
| Persson, CG | 2 |
| Andersson, M | 3 |
| Schenkel, EJ | 2 |
| Mansfield, LE | 1 |
| Limon, L | 1 |
| Kockler, DR | 1 |
| Sabbah, A | 1 |
| Lee, DK | 2 |
| Jackson, CM | 1 |
| Ratner, P | 4 |
| Hampel, F | 3 |
| Gispert, J | 2 |
| Baena-Cagnani, CE | 2 |
| Gurné, SE | 1 |
| Stryszak, P | 1 |
| Stübner, P | 2 |
| Zieglmeyer, R | 1 |
| Harris, AG | 6 |
| deTineo, M | 4 |
| Naclerio, RM | 5 |
| Baroody, FM | 4 |
| Nathan, RA | 2 |
| Ratner, PH | 4 |
| Howland, WC | 2 |
| Arastu, R | 1 |
| Philpot, EE | 1 |
| Klein, KC | 1 |
| Baidoo, CA | 1 |
| Faris, MA | 1 |
| Rickard, KA | 1 |
| Topuz, B | 1 |
| Ogmen, GG | 1 |
| Currie, GP | 1 |
| Anderson, SD | 1 |
| Jahnz-Rózyk, K | 1 |
| Targowski, T | 1 |
| Głodzinska-Wyszogrodzka, E | 1 |
| Płusa, T | 1 |
| Farkas, H | 1 |
| Glass, DJ | 1 |
| Harper, AS | 1 |
| Crampton, HJ | 1 |
| White, MV | 1 |
| Hill, SL | 1 |
| Krouse, JH | 1 |
| Wilken, JA | 1 |
| Kane, RL | 1 |
| Ellis, AK | 2 |
| Rafeiro, E | 3 |
| Sullivan, CL | 1 |
| van Adelsberg, J | 1 |
| Philip, G | 2 |
| Pedinoff, AJ | 1 |
| Menten, J | 1 |
| See, S | 1 |
| Moinuddin, R | 2 |
| Maleckar, B | 1 |
| Satish, U | 1 |
| Streufert, S | 1 |
| Dewan, M | 1 |
| Voort, SV | 1 |
| Van Bavel, J | 2 |
| Howland, W | 2 |
| Bender, BG | 2 |
| Milgrom, H | 2 |
| Magnan, A | 1 |
| Saint-Martin, F | 1 |
| Dumur, JP | 1 |
| Pérez, I | 1 |
| Izquierdo, I | 1 |
| Ciprandi, G | 5 |
| Cirillo, I | 1 |
| Vizzaccaro, A | 1 |
| Tosca, MA | 3 |
| Uras, N | 1 |
| Karadag, A | 1 |
| Kurtaran, H | 1 |
| Yilmaz, T | 1 |
| Agrawal, DK | 1 |
| Kirtsreesakul, V | 1 |
| Blair, C | 2 |
| Yu, X | 1 |
| Thompson, K | 1 |
| Li, H | 1 |
| Zhang, H | 1 |
| Yin, J | 1 |
| Wang, R | 1 |
| Fang, Q | 1 |
| Riechelmann, H | 1 |
| Rossi, GA | 1 |
| Passalacqua, G | 3 |
| Bianchi, B | 2 |
| Le Grazie, C | 1 |
| Bloom, M | 1 |
| Staudinger, H | 1 |
| Herron, J | 1 |
| Pleskow, W | 1 |
| Grubbe, R | 1 |
| Weiss, S | 1 |
| Lutsky, B | 2 |
| Hyo, S | 1 |
| Kawada, R | 1 |
| Kitazawa, S | 1 |
| Takenaka, H | 1 |
| Conboy-Ellis, K | 1 |
| Liu, X | 1 |
| Xing, Z | 1 |
| Gao, Z | 1 |
| Reinartz, SM | 1 |
| Overbeek, SE | 1 |
| Kleinjan, A | 1 |
| van Drunen, CM | 1 |
| Braunstahl, GJ | 1 |
| Hoogsteden, HC | 1 |
| Cyr, MM | 1 |
| Hayes, LM | 1 |
| Crawford, L | 1 |
| Baatjes, AJ | 1 |
| Keith, PK | 2 |
| Denburg, JA | 1 |
| Falqués, M | 1 |
| Chuecos, F | 1 |
| Esbrí, R | 1 |
| Peris, F | 1 |
| Luria, X | 1 |
| Rosales, MJ | 1 |
| Green, GR | 1 |
| Zieglmayer, UP | 1 |
| Kavina, A | 1 |
| Marschall, K | 1 |
| Munzel, U | 1 |
| Petzold, U | 1 |
| Kirmaz, C | 1 |
| Aydemir, O | 1 |
| Bayrak, P | 1 |
| Yuksel, H | 2 |
| Ozenturk, O | 1 |
| Degirmenci, S | 1 |
| Shedden, A | 1 |
| Jalowayski, AA | 1 |
| Vogt, K | 1 |
| Iezzoni, D | 1 |
| Prenner, B | 1 |
| Kim, K | 1 |
| Gupta, S | 1 |
| Khalilieh, S | 1 |
| Kantesaria, B | 1 |
| Manitpisitkul, P | 1 |
| Wang, Z | 1 |
| Tworek, D | 2 |
| Bocheńska-Marciniak, M | 2 |
| Kupczyk, M | 2 |
| Raphael, GD | 1 |
| Angello, JT | 1 |
| Druce, HM | 1 |
| Keskin, O | 2 |
| Alyamac, E | 1 |
| Tuncer, A | 2 |
| Dogan, C | 2 |
| Adalioglu, G | 2 |
| Sekerel, BE | 2 |
| Spangler, DL | 1 |
| Brunton, S | 1 |
| Blaiss, MS | 2 |
| Bordignon, V | 1 |
| Burastero, SE | 1 |
| Rak, S | 1 |
| Yang, WH | 1 |
| Pedersen, MR | 1 |
| Lehman, JM | 1 |
| Dizdar, EA | 1 |
| Kalayci, O | 1 |
| Pradalier, A | 1 |
| Neukirch, C | 1 |
| Devillier, P | 2 |
| Luciuk, G | 1 |
| Ousler, GW | 1 |
| Workman, DA | 1 |
| Pinar, E | 1 |
| Eryigit, O | 1 |
| Oncel, S | 1 |
| Calli, C | 1 |
| Yilmaz, O | 1 |
| Bogacka, E | 1 |
| Sterchaluk-Grzyb, E | 1 |
| Buczyłko, K | 1 |
| Chwała, C | 1 |
| Zielińska-Bliźniewska, H | 1 |
| Wagner, A | 1 |
| Dzwonnik, A | 1 |
| Roche, N | 1 |
| Faisy, C | 1 |
| Mucha, SM | 1 |
| Kleine-Tebbe, J | 1 |
| Josties, C | 1 |
| Frank, G | 1 |
| Stalleicken, D | 1 |
| Buschauer, A | 1 |
| Schunack, W | 1 |
| Kunkel, G | 1 |
| Czarnetzki, B | 1 |
| Siergiejko, Z | 2 |
| Michalska, I | 1 |
| Buko, Z | 2 |
| Swiderska, M | 1 |
| Chyrek-Borowska, S | 2 |
| Svensson, C | 1 |
| Enander, I | 1 |
| Bronsky, E | 2 |
| Boggs, P | 2 |
| Findlay, S | 1 |
| Gawchik, S | 1 |
| Georgitis, J | 2 |
| Mansmann, H | 1 |
| Sholler, L | 1 |
| Wolfe, J | 1 |
| Meltzer, E | 2 |
| Morris, R | 1 |
| Buscaglia, S | 2 |
| Catrullo, A | 2 |
| Marchesi, E | 3 |
| Tarchalska-Kryńska, B | 1 |
| Zawisza, E | 1 |
| Lee, ST | 1 |
| Amin, MJ | 1 |
| Bahmer, FA | 1 |
| Chervinsky, P | 3 |
| Banov, C | 1 |
| Vande Souwe, R | 1 |
| Greenstein, S | 1 |
| Dolovich, J | 2 |
| Moote, DW | 1 |
| Mazza, JA | 1 |
| Clermont, A | 1 |
| PetitClerc, C | 1 |
| Vuurman, EF | 1 |
| van Veggel, LM | 1 |
| Uiterwijk, MM | 1 |
| Leutner, D | 1 |
| O'Hanlon, JF | 1 |
| Jordana, G | 1 |
| Drouin, MA | 1 |
| Gold, M | 1 |
| Robson, R | 1 |
| Stepner, N | 1 |
| Yang, W | 1 |
| Weiler, JM | 2 |
| Widlitz, MD | 2 |
| Nielsen, L | 1 |
| Johnsen, CR | 1 |
| Mosbech, H | 1 |
| Malling, HJ | 1 |
| Kroczyńska-Bednarek, J | 1 |
| Gondorowicz, K | 1 |
| Kalinowska-Graczyk, M | 1 |
| Grzelewska-Rzymowska, I | 1 |
| Rozniecki, J | 1 |
| Hebert, JR | 1 |
| Nolop, K | 1 |
| Lutsky, BN | 1 |
| Frossard, N | 2 |
| Lacronique, J | 2 |
| Melac, M | 2 |
| Benabdesselam, O | 2 |
| Braun, JJ | 1 |
| Glasser, N | 2 |
| Pauli, G | 3 |
| Géhanno, P | 1 |
| Desfougeres, JL | 1 |
| Clark, RH | 1 |
| Gervais, P | 1 |
| Campbell, A | 1 |
| Chanal, I | 2 |
| Czarlewski, W | 3 |
| Michel, FB | 5 |
| Pronzato, C | 1 |
| Ricca, V | 1 |
| Aaronson, D | 1 |
| Beaucher, W | 1 |
| Berkowitz, R | 2 |
| Chen, R | 1 |
| Cohen, R | 1 |
| Fourre, J | 1 |
| Grossman, J | 2 |
| Pedinoff, A | 1 |
| Stricker, W | 1 |
| Wanderer, A | 1 |
| Pospelova, RA | 1 |
| Akimova, LG | 1 |
| Kolganova, NA | 1 |
| Zlatinskaia, GR | 1 |
| Serra, HA | 1 |
| Alves, O | 1 |
| Rizzo, LF | 1 |
| Devoto, FM | 1 |
| Ascierto, H | 1 |
| Briscoe, M | 2 |
| Cerqueti, P | 1 |
| Tosca, M | 1 |
| Fiorino, N | 1 |
| Cougnard, J | 2 |
| van Bavel, JH | 1 |
| Martin, BG | 1 |
| Hampel, FC | 1 |
| Rogenes, PR | 1 |
| Westlund, RE | 1 |
| Bowers, BW | 1 |
| Cook, CK | 1 |
| Rihoux, JP | 1 |
| Donnelly, F | 1 |
| Burtin, B | 1 |
| Kane, KY | 1 |
| Ellis, MR | 1 |
| Juniper, EF | 2 |
| Kaiser, HB | 2 |
| Banov, CH | 2 |
| Berkowitz, RR | 1 |
| Bernstein, DI | 1 |
| Bronsky, EA | 2 |
| Georgitis, JW | 2 |
| Mendelson, LM | 1 |
| Rooklin, AR | 1 |
| Sholler, LJ | 1 |
| Stricker, WW | 1 |
| Harrison, JE | 1 |
| Danzig, MR | 1 |
| Lorber, RR | 1 |
| Gawchik, SM | 1 |
| Lim, J | 2 |
| Persi, L | 1 |
| Tisserand, B | 1 |
| Stone, BD | 1 |
| Kósa, L | 1 |
| Fineman, SM | 1 |
| Lieberman, P | 1 |
| Miles, RM | 1 |
| McFadden, EA | 1 |
| Gungor, A | 1 |
| Ng, B | 1 |
| Mamikoglu, B | 1 |
| Corey, J | 1 |
| Kaliner, M | 1 |
| Weiler, J | 1 |
| Malmstrom, K | 1 |
| Prenner, BM | 2 |
| Wei, LX | 1 |
| Weinstein, SF | 1 |
| Wolfe, JD | 1 |
| Condemi, J | 1 |
| Schulz, R | 1 |
| Lim, JC | 1 |
| Georges, GC | 1 |
| Gates, D | 1 |
| Scharf, M | 1 |
| Greiding, L | 1 |
| Ramon, F | 1 |
| Heithoff, K | 1 |
| Herron, JM | 1 |
| Banfield, C | 1 |
| Padhi, D | 1 |
| Affrime, MB | 1 |
| Simons, FE | 2 |
| Johnston, L | 1 |
| Simons, KJ | 1 |
| Foresi, A | 1 |
| Capano, D | 1 |
| Geha, RS | 1 |
| McCormick, DR | 1 |
| McClellan, K | 1 |
| Jarvis, B | 1 |
| Doggrell, SA | 1 |
| Schenkel, E | 1 |
| Kaszuba, SM | 1 |
| Haney, L | 1 |
| Chapman, D | 1 |
| Kramer, B | 1 |
| Frantz, J | 1 |
| Orr, LC | 1 |
| Coutie, WJ | 1 |
| Pullerits, T | 1 |
| Praks, L | 1 |
| Ristioja, V | 1 |
| Lötvall, J | 1 |
| Stübner, UP | 1 |
| Small, P | 1 |
| Boner, AL | 2 |
| Richelli, C | 2 |
| Castellani, C | 1 |
| Andreoli, A | 2 |
| Herman, D | 1 |
| Arnaud, A | 1 |
| Dry, J | 1 |
| Latil, G | 1 |
| Perrin-Fayolle, M | 1 |
| Vervloet, D | 1 |
| Lisiecka, MZ | 1 |
| Frølund, L | 3 |
| Jäger, S | 1 |
| Berger, U | 1 |
| Olsen, OT | 1 |
| Nüchel Petersen, L | 1 |
| Høi, L | 1 |
| Lorentzen, KA | 1 |
| Hindberg Rasmussen, W | 1 |
| Svendsen, UG | 1 |
| Iudice, A | 1 |
| Ruffoni, S | 1 |
| Baumgarten, C | 1 |
| Pipkorn, U | 1 |
| Katelaris, C | 1 |
| Irander, K | 1 |
| Odkvist, LM | 1 |
| Ohlander, B | 1 |
| Lebel, B | 1 |
| Morel, A | 1 |
| Storms, WW | 1 |
| Bodman, SF | 1 |
| Dockhorn, RJ | 2 |
| Jarmoszuk, I | 1 |
| Zeitz, HJ | 1 |
| McGeady, SJ | 1 |
| Pinnas, JL | 1 |
| Clissold, SP | 1 |
| Sorkin, EM | 1 |
| Goa, KL | 1 |
| Lanier, BQ | 1 |
| Linzmayer, MI | 1 |
| Moss, BA | 1 |
| Selner, JC | 1 |
| Miglioranzi, P | 1 |
| Del Carpio, J | 2 |
| Kabbash, L | 1 |
| Turenne, Y | 2 |
| Prevost, M | 2 |
| Hebert, J | 2 |
| Bedard, PM | 1 |
| Nedilski, M | 1 |
| Gutkowski, A | 2 |
| Schulz, J | 2 |
| Bruttmann, G | 1 |
| Pedrali, P | 1 |
| Weeke, B | 1 |
| Wolff, HH | 1 |
| Christophers, E | 1 |
| Bedard, P | 1 |
| Yeadon, C | 1 |
| Oei, HD | 1 |
| Bergner, A | 1 |
| Connell, JT | 1 |
| Falliers, CJ | 1 |
| Grabiec, SV | 1 |
| Shellenberger, MK | 1 |
| Skassa-Brociek, W | 1 |
| Montes, F | 1 |
| Verdier, M | 1 |
| Schwab, D | 1 |
| Lherminier, M | 1 |
| Schultze-Wernighaus, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis[NCT01108783] | Phase 3 | 720 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine[NCT02513290] | Phase 4 | 73 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria[NCT01081574] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms[NCT00311844] | Phase 4 | 41 participants (Actual) | Interventional | 2005-03-01 | Completed | ||
| Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit[NCT00423995] | Phase 3 | 379 participants (Actual) | Interventional | 2006-11-01 | Completed | ||
| Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)[NCT00406783] | Phase 3 | 547 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen[NCT00867191] | Phase 4 | 233 participants (Actual) | Interventional | 2002-02-01 | Completed | ||
| Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927] | Phase 4 | 60 participants (Anticipated) | Interventional | 2020-12-12 | Recruiting | ||
| Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020] | Phase 2 | 138 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)[NCT00405964] | Phase 3 | 716 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Prescription Methods Assessment Project (PMAP)[NCT00393653] | 800 participants (Anticipated) | Interventional | 2006-10-31 | Terminated (stopped due to Funding ended early) | |||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832] | 20 participants | Interventional | 2005-03-31 | Completed | |||
| A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001[NCT00963469] | Phase 3 | 1,079 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Evaluation of the Efficacy and Safety of Desloratadine Syrup in Children Suffering From Seasonal Allergic Rhinitis With or Without Intermittent Asthma[NCT00805324] | Phase 3 | 54 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Leukotriene D4 Nasal Provocation Test: Rationale, Methodology, Diagnostic Value and Its Impact on Airway Inflammation in Allergic Rhinitis With or Without Asthma[NCT01963741] | 60 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| A Proof of Concept Study to Evaluate Comparative Efficacy of an Azelastine/Fluticasone Combination Nasal Spray vs. Twice the Dose of Fluticasone in Persistent Allergic Rhinitis[NCT00845598] | Phase 4 | 0 participants (Actual) | Interventional | 2010-08-31 | Withdrawn (stopped due to Could not get IMP) | ||
| As Needed Versus Regular Use of Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis: A Randomized Controlled Trial[NCT05299086] | 68 participants (Anticipated) | Interventional | 2022-04-04 | Recruiting | |||
| A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Fall Study[NCT00963599] | Phase 3 | 907 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The RQLQ-S questionnaire consists of 28 questions grouped into 7 domains. Each question is scored on a scale of 0 (not troubled with symptoms) to 6 (extremely troubled with symptoms). The total RQLQ-S score is the average score of the 28 questions which consisted of a total of 7 domains. (NCT00406783)
Timeframe: 15 days
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | -1.1 |
| Placebo Tablet | -0.73 |
The RQLQ-S questionnaire consists of 28 questions grouped into 7 domains. Each question is scored on a scale of 0 (not troubled with symptoms) to 6 (extremely troubled with symptoms). The total RQLQ-S score is the average score of the 28 questions which consisted of a total of 7 domains. (NCT00406783)
Timeframe: Baseline
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | 2.96 |
| Placebo Tablet | 2.80 |
AM/PM is the average of separate morning (AM) and evening (PM) evaluations. T5SS = the sum of the individual scores for nasal congestion/stuffiness, sneezing, rhinorrhea/nasal discharge, nasal pruritis, and ocular pruritis. Each individual symptom/sign was scored from 0 (none) to 3 (severe). (NCT00406783)
Timeframe: 15 days
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | -3.01 |
| Placebo Tablet | -2.13 |
AM/PM is the average of separate morning (AM) and evening (PM) evaluations. T5SS = the sum of the individual scores for nasal congestion/stuffiness, sneezing, rhinorrhea/nasal discharge, nasal pruritis, and ocular pruritis. Each individual symptom/sign was scored from 0 (none) to 3 (severe). (NCT00406783)
Timeframe: Baseline
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| 5-mg Desloratadine Tablet | 8.5 |
| Placebo Tablet | 8.33 |
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 85. AM/PM is the average of separate AM and PM evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Days 1-85
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Days 1-85 | |
| 5-mg Desloratadine Tablet | 9.63 | -4.50 |
| Placebo Tablet | 9.55 | -3.61 |
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Days 1-29
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Days 1-29 | |
| 5-mg Desloratadine Tablet | 9.63 | -3.76 |
| Placebo Tablet | 9.55 | -2.87 |
The RQLQ-S was only completed for participants above 18 years of age. The RQLQ-S was not available for participants 12 to 17 years of age. This questionnaire asked questions pertaining to daily activities, sleep, non-nose eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotions. The scale went from 0 (not troubled) to 6 (extremely troubled). A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Day 29
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Day 29 | |
| 5-mg Desloratadine Tablet | 3.30 | -1.35 |
| Placebo Tablet | 3.15 | -0.95 |
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
Composite Symptoms Scores were computed as the average of Daytime Nasal Scores [Score 0 (best) to 3 (worst)] and Nighttime Symptoms Scores [Score 0 (best) to 3 (worst)]. (NCT00963469)
Timeframe: Baseline and first 2 Weeks of treatment period (from randomization through the end of Week 2)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.21 |
| Montelukast | -0.30 |
| Loratadine | -0.36 |
"Mean change from baseline in Daytime Eye Symptoms scores.~Patients were asked to rate each of the 4 eye symptom of tearing, itchy, red, and puffy eyes daily on a 4-point scale [Score 0 (best) to 3 (worst)]. The average of the 4 individual eye symptoms scores was reported as the Daytime Eye Symptoms Score." (NCT00963469)
Timeframe: Baseline and first 2 Weeks of treatment period (from randomization through the end of Week 2)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.18 |
| Montelukast | -0.28 |
| Loratadine | -0.33 |
"Mean change from baseline in Daytime Nasal Symptoms Score.~Patients were asked to rate each nasal symptom of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4- point scale [Score 0 (best) to 3 (worse)]. The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal Symptoms Score." (NCT00963469)
Timeframe: Baseline and first 2 Weeks of treatment period (from randomization through the end of Week 2)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.23 |
| Montelukast | -0.33 |
| Loratadine | -0.45 |
"Mean change from baseline in Nighttime Symptoms Score.~Patients were asked to rate each symptom daily on a 4-point scale [Score 0 (best) to 3 (worse)], and the combined score of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings was reported as the Nighttime Symptoms Score." (NCT00963469)
Timeframe: Baseline and first 2 Weeks of treatment period (from randomization through the end of Week 2)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.18 |
| Montelukast | -0.28 |
| Loratadine | -0.25 |
Patients completed a Rhinoconjunctivitis Quality-of-Life Questionnaire-28 questions on a 7-point scale [0(best) to 6(worst)] across 7 domains: activity,sleep,non-nose/eye symptoms,practical problems,nasal symptoms, eye symptoms, and emotions. The scores for each domain were averaged, then scores for the 7 domains were averaged for an overall score. (NCT00963469)
Timeframe: Baseline and first 2 Weeks of treatment period (from randomization through the end of Week 2)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.55 |
| Montelukast | -0.85 |
| Loratadine | -0.85 |
An evaluation by the patient, administered after the first 2 weeks of treatment using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study. (NCT00963469)
Timeframe: After first 2 weeks of treatment
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.73 |
| Montelukast | 2.43 |
| Loratadine | 2.30 |
An evaluation by the physician, administered after the first 2 weeks of treatment using a 7-point scale [Score 0 (best) to 6 (worst)], of the change in symptoms as compared to the beginning of the study. (NCT00963469)
Timeframe: After first 2 weeks of treatment
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.75 |
| Montelukast | 2.36 |
| Loratadine | 2.38 |
Composite Symptoms scores were computed as the average of the Daytime Nasal Symptoms scores and Nighttime Symptoms scores collected on a 4 point scale (0 (best) to 3 (worst)). (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.2 |
| Montelukast | -0.40 |
| Loratadine | -0.41 |
| Montelukast/Loratadine | -0.45 |
Mean change from baseline in Daytime Eye Symptoms scores. Patients were asked to rate each of the 4 eye symptom of tearing, itchy, red, and puffy eyes daily on a 4-point scale (0 (best) to 3 (worst)). The average of the 4 individual eye symptoms scores was reported as the Daytime Eye Symptoms Score. (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.14 |
| Montelukast | -0.35 |
| Loratadine | -0.38 |
| Montelukast/Loratadine | -0.41 |
Patients were asked to rate the nasal symptom of Congestion daily on a 4-point scale (0 (best) to 3 (worst)). (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.19 |
| Montelukast | -0.41 |
| Loratadine | -0.39 |
| Montelukast/Loratadine | -0.43 |
Patients were asked to rate the nasal symptom of Nasal Itching daily on a 4-point scale (0 (best) to 3 (worst)). (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.26 |
| Montelukast | -0.49 |
| Loratadine | -0.56 |
| Montelukast/Loratadine | -0.62 |
Mean change from baseline in Daytime Nasal Symptoms score. Patients were asked to rate each of the 4 nasal symptoms of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4-point scale (0 (best) to 3 (worst)). The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal Symptoms Score. (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.26 |
| Montelukast | -0.48 |
| Loratadine | -0.52 |
| Montelukast/Loratadine | -0.58 |
Patients were asked to rate the nasal symptom of Rhinorrhea daily on a 4-point scale (0 (best) to 3 (worst)). (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.25 |
| Montelukast | -0.53 |
| Loratadine | -0.51 |
| Montelukast/Loratadine | -0.59 |
Patients were asked to rate the nasal symptom of Sneezing daily on a 4-point scale (0 (best) to 3 (worst)). (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.26 |
| Montelukast | -0.46 |
| Loratadine | -0.59 |
| Montelukast/Loratadine | -0.67 |
Patients were asked to rate the symptom of Nasal Congestion Upon Awakening daily on a 4-point scale (0 (best) to 3 (worst)). (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.15 |
| Montelukast | -0.35 |
| Loratadine | -0.30 |
| Montelukast/Loratadine | -0.32 |
Mean change from baseline in Nighttime Symptoms Score. Patients were asked to rate each symptom daily on a 4-point scale (0 (best) to 3 (worst)), and the combined score of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings was reported as the Nighttime Symptoms Score. (NCT00963599)
Timeframe: Baseline and Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.12 |
| Montelukast | -0.29 |
| Loratadine | -0.26 |
| Montelukast/Loratadine | -0.28 |
Patients completed a Rhinoconjunctivitis Quality-of-Life Questionnaire, 28 questions on a 7-point scale [0(best) to 6(worst)] across 7 domains: activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, emotional. Scores per domain were averaged, then scores for the 7 domains were averaged for an overall score. (NCT00963599)
Timeframe: Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | -0.80 |
| Montelukast | -1.09 |
| Loratadine | -1.06 |
| Montelukast/Loratadine | -1.16 |
An evaluation by the patient, administered at the last visit (or upon discontinuation) using a 7-point scale, of the change in symptoms as compared to the beginning of the study. Responses were assigned numerical values from 0 (very much better) to 6 (very much worse). (NCT00963599)
Timeframe: Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | 2.37 |
| Montelukast | 2.10 |
| Loratadine | 2.00 |
| Montelukast/Loratadine | 1.92 |
An evaluation by the physician, administered at the last visit (or upon discontinuation) using a 7-point scale, of the change in symptoms as compared to the beginning of the study. Responses were assigned numerical values from 0 (very much better) to 6 (very much worse). (NCT00963599)
Timeframe: Week 2
| Intervention | Units on a Scale (Least Squares Mean) |
|---|---|
| Placebo | 2.35 |
| Montelukast | 2.13 |
| Loratadine | 2.05 |
| Montelukast/Loratadine | 1.99 |
34 reviews available for loratadine and Hay Fever
| Article | Year |
|---|---|
[Meta-analysis of leukotriene receptor antagonist montelukast in the treatment of allergic rhinitis].
Topics: Acetates; Cyclopropanes; Drug Therapy, Combination; Humans; Leukotriene Antagonists; Loratadine; Nos | 2014 |
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses.
Topics: Ambrosia; Anti-Allergic Agents; Humans; Loratadine; Mometasone Furoate; Phleum; Rhinitis, Allergic, | 2016 |
Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.
Topics: Clinical Trials as Topic; Drug Combinations; Histamine H1 Antagonists, Non-Sedating; Humans; Loratad | 2009 |
A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cetirizine; Child; Clinical Trials as Topic; Female; His | 2009 |
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine | 2010 |
The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis--a meta-analysis.
Topics: Anti-Allergic Agents; Cetirizine; Humans; Loratadine; Rhinitis, Allergic, Perennial; Rhinitis, Aller | 2011 |
Impact and modulation of nasal obstruction.
Topics: Histamine H1 Antagonists; Humans; Loratadine; Nasal Obstruction; Randomized Controlled Trials as Top | 2002 |
Advances in allergy management.
Topics: Histamine H1 Antagonists; Humans; Inflammation Mediators; Loratadine; Nasal Obstruction; Quality of | 2002 |
Desloratadine: a nonsedating antihistamine.
Topics: Adult; Area Under Curve; Child; Female; Half-Life; Histamine H1 Antagonists, Non-Sedating; Humans; L | 2003 |
[The place of new antihistamines in allergy management. Apropos of desloratadine].
Topics: Anti-Allergic Agents; Double-Blind Method; Half-Life; Histamine H1 Antagonists; Histamine Release; H | 2002 |
Desloratadine for allergic rhinitis.
Topics: Administration, Oral; Adolescent; Adult; Drug Administration Schedule; Drug Costs; Histamine H1 Anta | 2003 |
Anti-inflammatory properties of desloratadine.
Topics: Cell Adhesion; Cytokines; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Models, Immuno | 2004 |
[Oral second generation antihistamines in allergic rhinitis].
Topics: Administration, Oral; Adult; Anti-Allergic Agents; Cetirizine; Child; Conjunctivitis, Allergic; Cont | 2005 |
Management of seasonal allergic rhinitis: comparative efficacy of the newer-generation prescription antihistamines.
Topics: Adolescent; Adult; Cetirizine; Child; Child, Preschool; Histamine H1 Antagonists; Histamine H1 Antag | 2005 |
A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis.
Topics: Cetirizine; Histamine Antagonists; Humans; Loratadine; Nose; Piperazines; Quality of Life; Randomize | 2005 |
Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis.
Topics: Adult; Butyrophenones; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Mul | 2005 |
Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Chronic Disease; Cl | 2005 |
The safety and efficacy of desloratadine for the management of allergic disease.
Topics: Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Product Surveillance, Postmarketing; Ran | 2005 |
A review of the evidence from comparative studies of levocetirizine and desloratadine for the symptoms of allergic rhinitis.
Topics: Cetirizine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Piperazines; Retrospective S | 2006 |
Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.
Topics: Administration, Oral; Age Factors; Dose-Response Relationship, Drug; Electrocardiography; Histamine | 2006 |
Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis.
Topics: Central Nervous System; Cetirizine; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating | 2006 |
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
Desloratadine treatment for intermittent and persistent allergic rhinitis: a review.
Topics: Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Practice Guidelines as Topic; Quality of | 2007 |
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Topics: Cetirizine; Drug Interactions; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, | 2008 |
Topical levocabastine--an effective alternative to oral antihistamines in seasonal allergic rhinoconjunctivitis.
Topics: Administration, Oral; Administration, Topical; Clinical Trials as Topic; Conjunctivitis, Allergic; D | 1995 |
A comparison of the clinical efficacy and safety of intranasal fluticasone propionate and antihistamines in the treatment of rhinitis.
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Anti-Inflammatory Agents; Clinical | 2000 |
Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis.
Topics: Chemotaxis, Leukocyte; Cholinergic Antagonists; Eosinophils; Histamine H1 Antagonists; Humans; Lorat | 2001 |
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma.
Topics: Asthma; Cholinergic Antagonists; Eosinophils; Histamine H1 Antagonists; Humans; Loratadine; Respirat | 2001 |
Triamcinolone: new and old indications.
Topics: Administration, Intranasal; Adult; Aerosols; Androstadienes; Anti-Inflammatory Agents; Arthritis, Rh | 2001 |
Clinical evidence for antileukotriene therapy in the management of allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cyclopropanes; Hista | 2002 |
Comparative effects of terfenadine and loratadine in the treatment of hay fever.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Loratadine; Male; Middle Aged; Rhinitis, All | 1991 |
H1-receptor antagonist treatment of seasonal allergic rhinitis.
Topics: Astemizole; Benzhydryl Compounds; Benzimidazoles; Cetirizine; Chlorpheniramine; Clemastine; Cyprohep | 1990 |
Three new non-sedative antihistamines: worth keeping an eye open for.
Topics: Cetirizine; Cyproheptadine; Histamine H1 Antagonists; Humans; Hydroxyzine; Loratadine; Rhinitis, All | 1990 |
Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
Topics: Animals; Common Cold; Cyproheptadine; Female; Humans; Loratadine; Male; Rhinitis, Allergic, Perennia | 1989 |
146 trials available for loratadine and Hay Fever
| Article | Year |
|---|---|
Efficacy of Desloratadine and Levocetirizine in Patients with Cedar Pollen-Induced Allergic Rhinitis: A Randomized, Double-Blind Study.
Topics: Adult; Cedrus; Cetirizine; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists | 2019 |
Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.
Topics: Anti-Allergic Agents; Cetirizine; Child; Female; Headache; Humans; Loratadine; Male; Pharyngitis; Rh | 2017 |
[The effect of combined therapy on seasonal allergic rhinitis].
Topics: Administration, Intranasal; Budesonide; Double-Blind Method; Glucocorticoids; Humans; Leukotriene An | 2016 |
Combination therapy with montelukast and loratadine alleviates pharyngolaryngeal symptoms related to seasonal allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Allergens; Anti-Allergic Agents; Cryptomeria; Cyclopropanes; Double-Bli | 2019 |
Protective efficacy of sunglasses on the conjunctival symptoms of seasonal rhinitis.
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Conjunctivitis, Allergic; Eye Protective Devices; Femal | 2013 |
Tap water nasal irrigation in adults with seasonal allergic rhinitis: a randomized double-blind study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drinking Water; Female; Histamine H1 Antagoni | 2014 |
Efficacy and safety of the probiotic Lactobacillus paracasei LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study).
Topics: Adult; Dietary Supplements; Double-Blind Method; Endpoint Determination; Female; Histamine Antagonis | 2014 |
[The investigation of efficacy and safety of Aerius to seasonal allergic rhinitis].
Topics: Adolescent; Adult; Anti-Allergic Agents; Child; Female; Histamine H1 Antagonists; Humans; Loratadine | 2008 |
Clinical and biochemical effects of a combination botanical product (ClearGuard) for allergy: a pilot randomized double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Bidens; Cinnamomum zeylanicum; Cross-Over Studies; Do | 2008 |
[The effect of desloratadine on quality of life of patients with seasonal allergic rhinitis].
Topics: Adolescent; Adult; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lora | 2008 |
Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine.
Topics: Acetates; Adolescent; Adult; Aged; Cetirizine; Chronic Disease; Cross-Over Studies; Cyclopropanes; D | 2008 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
Topics: Adolescent; Adult; Aged; Area Under Curve; Benzimidazoles; Child; Double-Blind Method; Drug-Related | 2009 |
[Observation on cardiovascular safety of loratadine in treatment of persistent allergic rhinitis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Heart Rate; Histamine H1 Antagonists, | 2008 |
Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms.
Topics: Administration, Oral; Adult; Aged; Conjunctivitis, Allergic; Cross-Over Studies; Dose-Response Relat | 2009 |
Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit.
Topics: Acetates; Administration, Intranasal; Adult; Ambrosia; Anti-Allergic Agents; Anti-Asthmatic Agents; | 2009 |
[Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis].
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Female; Histamine H1 Antagonists, Non-Sedating; Human | 2009 |
Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Bronchodilator Agents; Child; Double-Blind Method; Drug Synergism; Drug The | 2009 |
Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study.
Topics: Adult; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male | 2009 |
Desloratadine for the treatment of cypress pollen-induced allergic rhinitis.
Topics: Adult; Antigens, Plant; Cupressus; Disease Progression; Double-Blind Method; Female; France; Histami | 2009 |
Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Beclomethasone; Cyclopropanes; Double-Blind Me | 2009 |
Onset of action of loratadine/montelukast in seasonal allergic rhinitis patients exposed to grass pollen.
Topics: Acetates; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Cross-Over Studies; Cyclopropanes; Dou | 2010 |
Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study.
Topics: Adult; Disease Progression; Female; Follow-Up Studies; Histamine H1 Antagonists, Non-Sedating; Human | 2010 |
Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine.
Topics: Adult; Allergens; Anti-Allergic Agents; Bronchial Provocation Tests; Chemokines; Cross-Over Studies; | 2011 |
Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Anti-Allergic Agents; Betamethasone; | 2013 |
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Child; Double-Blind Method; Drug A | 2002 |
Single-patient drug trial methodology for allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Chlorpheniramine; Clinical Trials as Topic; Da | 2002 |
A comparative study of the side effects between pseudoephedrine in Loratadine plus Pseudoephedrine Sulfate Repetabs Tables and loratadine + pseudoephedrine tablet in treatment of allergic rhinitis in Thai patients.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Combinations; Ephedrine; Female; Histamine | 2002 |
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.
Topics: Adult; Air Pollutants; Allergens; Cross-Over Studies; Double-Blind Method; Environmental Exposure; F | 2002 |
Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis.
Topics: Adolescent; Adult; Allergens; alpha-Macroglobulins; Betula; Cross-Over Studies; Double-Blind Method; | 2002 |
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion.
Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Drug Administration Schedule; Female; Histamin | 2002 |
Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis.
Topics: Adult; Ambrosia; Butyrophenones; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hist | 2003 |
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthm | 2003 |
Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Environmental Exposure | 2003 |
Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis.
Topics: Acetates; Adult; Androstadienes; Anti-Inflammatory Agents; Cyclopropanes; Double-Blind Method; Drug | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age | 2003 |
Montelukast as an adjuvant to mainstay therapies in patients with seasonal allergic rhinitis.
Topics: Acetates; Adjuvants, Immunologic; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Cyclopropane | 2003 |
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.
Topics: Acetates; Adult; Cross-Over Studies; Cyclopropanes; Diuretics, Osmotic; Double-Blind Method; Histami | 2003 |
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis].
Topics: Adult; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Middle Aged; Rhinit | 2003 |
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo
Topics: Adolescent; Adult; Aged; Allergens; Anti-Allergic Agents; Child; Conjunctivitis, Allergic; Double-Bl | 2003 |
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Double-Blind Method; Dru | 2003 |
The effects of montelukast on intradermal wheal and flare.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Candida albicans; Cyclopropanes; Double-Bli | 2003 |
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis.
Topics: Allergens; Ambrosia; Anti-Allergic Agents; Arousal; Cognition; Diphenhydramine; Double-Blind Method; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Female; | 2003 |
Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Ambrosia; Anti-Allergic Agents; Cyclopropanes; Double-Blind Method; Dru | 2004 |
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine.
Topics: Adolescent; Adult; Cross-Over Studies; Decision Making; Double-Blind Method; Female; Histamine H1 An | 2004 |
Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Butyrophenones; Child; Double-Blind Method; Female; Histamine H1 Antagonist | 2004 |
Comparison of the effects of fluticasone propionate aqueous nasal spray and loratadine on daytime alertness and performance in children with seasonal allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Androstadienes; Anti-Allergic Agents; | 2004 |
Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU).
Topics: Adolescent; Adult; Cetirizine; Cohort Studies; Double-Blind Method; Female; Histamine H1 Antagonists | 2004 |
A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Cross-Over Studies; Cyproheptadine; Dose-Respo | 2004 |
A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis.
Topics: Administration, Oral; Butyrophenones; Cross-Over Studies; Dose-Response Relationship, Drug; Double-B | 2004 |
Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study.
Topics: Adult; Cetirizine; Double-Blind Method; Eosinophils; Female; Histamine H1 Antagonists; Humans; Inter | 2004 |
A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC).
Topics: Cetirizine; Cross-Over Studies; Double-Blind Method; Environmental Exposure; Female; Histamine H1 An | 2004 |
[Clinical examination of mizolastine in the seasonal allergic rhinitis].
Topics: Adolescent; Adult; Aged; Benzimidazoles; Female; Histamine H1 Antagonists; Humans; Loratadine; Male; | 2004 |
Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis.
Topics: Child; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Pollen; Rhinitis, A | 2005 |
Safety of desloratadine syrup in children.
Topics: Acute Disease; Administration, Oral; Child; Child, Preschool; Double-Blind Method; Electrocardiograp | 2004 |
Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Double-Blind Method; Drug Combinations; Ephedrine; Female; Histamine | 2005 |
The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen.
Topics: Adult; Cetirizine; Cryptomeria; Double-Blind Method; Drug Administration Schedule; Female; Histamine | 2005 |
[The effect of antianaphylaxis drugs on specific IgE and eosinophil in serum of patients with allergic rhinitis].
Topics: Acetates; Adult; Cyclopropanes; Eosinophils; Female; Histamine H1 Antagonists, Non-Sedating; Humans; | 2005 |
Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients.
Topics: Adult; Asthma; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Inflammation; Loratadine; Mal | 2005 |
The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study.
Topics: Adolescent; Adult; Basophils; Cytokines; Eosinophils; Female; Histamine H1 Antagonists, Non-Sedating | 2005 |
Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy.
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Allergic Agents; Female; Histamine H1 Antagonist | 2006 |
Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial.
Topics: Adult; Demography; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lora | 2006 |
The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis.
Topics: Adult; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Histamine H1 Antagon | 2007 |
Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Diphenhydramine; Double-Blind Method; Female; | 2006 |
Do the leukotriene receptor antagonists work in children with grass pollen-induced allergic rhinitis?
Topics: Acetates; Anti-Allergic Agents; Anti-Asthmatic Agents; Area Under Curve; Child; Cross-Over Studies; | 2006 |
Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis.
Topics: Administration, Sublingual; Adolescent; Adult; Allergens; Child; Child, Preschool; Conjunctivitis, A | 2006 |
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Allergens; Anti-Allergic Agents; Conjunctivitis | 2007 |
The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis.
Topics: Adolescent; Albuterol; Bronchial Hyperreactivity; Bronchoconstrictor Agents; Bronchodilator Agents; | 2007 |
Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis.
Topics: Adult; Double-Blind Method; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male | 2007 |
Effectiveness of desloratadine 5 mg once daily in patients with symptoms of seasonal allergic rhinitis: results of a Canadian multicenter, open-label trial.
Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Anti-Allergic Agents; Canada; Child; | 2007 |
An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
Topics: Administration, Topical; Adolescent; Adult; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzazep | 2007 |
[The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].
Topics: Administration, Oral; Adult; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Broncho | 2005 |
Nasal challenge with allergen leads to maxillary sinus inflammation.
Topics: Adult; Albumins; Ambrosia; Anti-Allergic Agents; Cross-Over Studies; Double-Blind Method; Eosinophil | 2008 |
Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Double-Blind Metho | 2008 |
[The effect of loratadine on skin and bronchial reactivity and histamine liberation from basophils in patients with atopic asthma and allergic rhinitis].
Topics: Asthma; Basophils; Bronchial Provocation Tests; Histamine; Histamine Release; Humans; Loratadine; Rh | 1994 |
Loratadine reduces allergen-induced mucosal output of alpha 2-macroglobulin and tryptase in allergic rhinitis.
Topics: Adolescent; Adult; Allergens; alpha-Macroglobulins; Cell Count; Chymases; Cross-Over Studies; Dose-R | 1995 |
Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Double-Blind Method; Drug Therapy, Combination; E | 1995 |
Loratadine in the treatment of cough associated with allergic rhinoconjunctivitis.
Topics: Adult; Aged; Allergens; Conjunctivitis; Cough; Female; Humans; Loratadine; Male; Middle Aged; Pollen | 1995 |
Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Swedish GP Allergy Team.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aerosols; Aged; Conjunctivitis, Al | 1994 |
[Test for efficacy of cetirizine and loratadine as a treatment for seasonal allergic rhinitis in a 6 week cross-over comparative study].
Topics: Adolescent; Adult; Cetirizine; Conjunctivitis; Cross-Over Studies; Female; Humans; Loratadine; Male; | 1994 |
Efficacy and safety of loratadine compared with astemizole in Malaysian patients with allergic rhinitis.
Topics: Astemizole; Double-Blind Method; Humans; Loratadine; Malaysia; Rhinitis, Allergic, Seasonal; Time Fa | 1994 |
[Loratadine in the treatment of seasonal allergic rhinitis].
Topics: Adolescent; Adult; Eosinophils; Female; Histamine H1 Antagonists; Humans; Loratadine; Male; Middle A | 1994 |
Once daily loratadine versus astemizole once daily.
Topics: Administration, Oral; Adolescent; Adult; Astemizole; Child; Dose-Response Relationship, Drug; Double | 1994 |
Efficacy of loratadine versus placebo in the prophylactic treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Loratadine | 1994 |
Seasonal allergic rhinitis and antihistamine effects on children's learning.
Topics: Child; Cognition; Diphenhydramine; Female; Humans; Hypersensitivity, Immediate; Learning; Loratadine | 1993 |
Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis.
Topics: Administration, Intranasal; Adolescent; Androstadienes; Anti-Allergic Agents; Child; Double-Blind Me | 1996 |
Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis.
Topics: Adolescent; Adult; Cetirizine; Child; Double-Blind Method; Female; Humans; Loratadine; Male; Middle | 1996 |
Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Immunologic; Double-Blind Method; Female; Histamine H1 Antagonist | 1996 |
[Bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and the influence of loratadine and beclomethasone on this hyperresponsiveness].
Topics: Adolescent; Adult; Anti-Allergic Agents; Beclomethasone; Bronchial Hyperreactivity; Female; Humans; | 1996 |
Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adult; Aged; Anti-Allergic Agents; | 1996 |
Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis.
Topics: Adult; Airway Resistance; Animals; Cetirizine; Cross-Over Studies; Double-Blind Method; Female; Hist | 1997 |
Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Androstadienes; Anti-Alle | 1997 |
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental | 1997 |
Reduction of soluble ICAM-1 levels in nasal secretion by H1-blockers in seasonal allergic rhinitis.
Topics: Adult; Albumins; Cetirizine; Double-Blind Method; Epithelial Cells; Histamine H1 Antagonists; Humans | 1997 |
Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression.
Topics: Adolescent; Adult; Blood Proteins; Cetirizine; Eosinophil Granule Proteins; Eosinophil Peroxidase; E | 1997 |
Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; E | 1997 |
Loratadine-pseudoephedrine in children with allergic rhinitis, a controlled double-blind trial.
Topics: Adolescent; Anti-Allergic Agents; Argentina; Bronchodilator Agents; Child; Child, Preschool; Cross-O | 1998 |
Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allergens; Anti-Allergic Agents; Cetirizine; Double-Blin | 1998 |
Loratadine reduces the expression of ICAM-1.
Topics: Adolescent; Adult; Anti-Allergic Agents; Conjunctiva; Conjunctivitis, Allergic; Double-Blind Method; | 1998 |
Changes in skin-test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis.
Topics: Adolescent; Adult; Allergens; Astemizole; Child; Conjunctiva; Dose-Response Relationship, Drug; Doub | 1998 |
A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Androstadienes; Anti-Inflammatory Agents; Doubl | 1998 |
Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Allergic Agents; Child; Delayed-Action Preparati | 1998 |
Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis.
Topics: Adult; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female | 1998 |
Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweed-induced allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adult; Anti-Allergic Agents; Anti-Inflammatory Age | 1997 |
Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine.
Topics: Adult; Allergens; Anti-Allergic Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Female; | 1999 |
Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Beclomethasone; Child | 1999 |
Loratadine/pseudoephedrine for nasal symptoms in seasonal allergic rhinitis: a double-blind, placebo-controlled study.
Topics: Adult; Anti-Allergic Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; | 2000 |
Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge.
Topics: Adult; Air Pollutants; Allergens; Anti-Allergic Agents; Double-Blind Method; Drug Combinations; Ephe | 2000 |
Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Cyclopropanes; Drug Therapy, Combination; F | 2000 |
Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Inflammatory Agents, | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Double-Blind Method; Drug Administration Schedule; Female; Histamine H1 An | 2000 |
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group.
Topics: Adolescent; Adult; Aged; Butyrophenones; Child; Double-Blind Method; Female; Histamine H1 Antagonist | 2000 |
Loratadine versus cetirizine: assessment of somnolence and motivation during the workday.
Topics: Adult; Anti-Allergic Agents; Cetirizine; Disorders of Excessive Somnolence; Double-Blind Method; Eff | 2000 |
The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years.
Topics: Anti-Allergic Agents; Biological Availability; Child, Preschool; Double-Blind Method; Drug Administr | 2000 |
Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children.
Topics: Anti-Allergic Agents; Cetirizine; Child; Cross-Over Studies; Double-Blind Method; Histamine H1 Antag | 2000 |
Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Cross-Over Studies; Double-Blind Method; Femal | 2000 |
Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine.
Topics: Child; Diphenhydramine; Female; Histamine H1 Antagonists; Humans; Learning; Loratadine; Male; Rhinit | 2001 |
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Circadian Rhythm; Dose-Response Relationship, Drug; Double-Blind Met | 2001 |
Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adrenal Cortex Hormones; Androstadienes; Anti-Alle | 2001 |
Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system.
Topics: Adolescent; Adult; Cetirizine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Lorata | 2001 |
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis.
Topics: Acetates; Adult; Anti-Allergic Agents; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Drug | 2002 |
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis.
Topics: Acetates; Administration, Intranasal; Adult; Androstadienes; Circadian Rhythm; Cyclopropanes; Double | 2002 |
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Loratadine | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
Topics: Acetates; Adult; Aged; Anti-Asthmatic Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Comb | 2002 |
Suppression of epicutaneous reactivity by terfenadine and loratadine.
Topics: Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Hypersensitivity; Lor | 1992 |
Comparison of the effects of loratadine and astemizole in the treatment of children with seasonal allergic rhinoconjunctivitis.
Topics: Adolescent; Astemizole; Child; Conjunctivitis, Allergic; Cyproheptadine; Female; Histamine Antagonis | 1992 |
[Clinical effectiveness and tolerance of loratadine versus cetirizine in the treatment of seasonal allergic rhinitis].
Topics: Adult; Cetirizine; Double-Blind Method; Drug Tolerance; Female; Humans; Loratadine; Male; Rhinitis, | 1992 |
[Loratadine in hay fever].
Topics: Administration, Intranasal; Administration, Oral; Adult; Beclomethasone; Double-Blind Method; Female | 1992 |
Onset and duration of the effects of three antihistamines in current use--astemizole, loratadine and terfenadine forte--studied during prolonged, controlled allergen challenges in volunteers.
Topics: Adult; Allergens; Astemizole; Double-Blind Method; Female; Humans; Loratadine; Male; Nasal Mucosa; P | 1992 |
Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow.
Topics: Adolescent; Adult; Aged; Conjunctivitis, Allergic; Double-Blind Method; Female; Humans; Loratadine; | 1992 |
Comparative effects of terfenadine and loratadine in the treatment of hay fever.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Loratadine; Male; Middle Aged; Rhinitis, All | 1991 |
Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Beclomethasone; Cyproheptadine; Doubl | 1991 |
Suppressive effect of loratadine on allergen-induced histamine release in the nose.
Topics: Adolescent; Adult; Allergens; Cyproheptadine; Double-Blind Method; Female; Histamine H1 Antagonists; | 1991 |
Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Cyproheptadine; Double-Blind Method; Female; Histamine Antagonists; Histami | 1990 |
Treatment of hay fever with loratadine--a new non-sedating antihistamine.
Topics: Clemastine; Cyproheptadine; Double-Blind Method; Drug Evaluation; Female; Histamine Antagonists; Hum | 1990 |
Antiallergic activity of H1-receptor antagonists assessed by nasal challenge.
Topics: Adult; Benzhydryl Compounds; Cyproheptadine; Double-Blind Method; Histamine H1 Antagonists; Histamin | 1988 |
SCH 434: a new antihistamine/decongestant for seasonal allergic rhinitis.
Topics: Adolescent; Adult; Child; Cyproheptadine; Delayed-Action Preparations; Double-Blind Method; Drug Com | 1989 |
Loratadine-pseudoephedrine combination versus placebo in patients with seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Child; Cyproheptadine; Drug Combinations; Ephedrine; Female; Histamine Anta | 1989 |
Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis.
Topics: Administration, Oral; Child; Child, Preschool; Chlorpheniramine; Cyproheptadine; Double-Blind Method | 1989 |
Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Benzhydryl Compounds; Cyproheptadine; Double-Blind Method; Drug Administration Sc | 1989 |
A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Child; Clinical Trials as Topic; Cyproheptadine; Doub | 1988 |
Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Benzhydryl Compounds; Clinical Trials as Topic; Cyproheptadine; Double-Blind Meth | 1988 |
Double-blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action.
Topics: Adolescent; Adult; Astemizole; Benzimidazoles; Clinical Trials as Topic; Cyproheptadine; Dose-Respon | 1988 |
Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis.
Topics: Capsules; Clemastine; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Histamine Antag | 1987 |
Double-blind placebo-controlled study of loratadine, mequitazine, and placebo in the symptomatic treatment of seasonal allergic rhinitis.
Topics: Adolescent; Adult; Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Female; Humans; Lo | 1988 |
[Disodium cromoglycate in comparison with antihistaminics (loratadine) in seasonal allergic rhinitis].
Topics: Adult; Clinical Trials as Topic; Cromolyn Sodium; Cyproheptadine; Histamine Antagonists; Humans; Lor | 1988 |
41 other studies available for loratadine and Hay Fever
| Article | Year |
|---|---|
Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Topics: Acetates; Administration, Oral; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Astemizole; Ceti | 2009 |
The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis.
Topics: Adolescent; Cost-Benefit Analysis; Female; France; Histamine H1 Antagonists, Non-Sedating; Humans; L | 2010 |
Ahh-choo! How to sneeze at allergies.
Topics: Adrenal Cortex Hormones; Cetirizine; Diphenhydramine; Health Behavior; Health Care Surveys; Histamin | 2010 |
You're the flight surgeon: ear, nose and throat conditions.
Topics: Adult; Aerospace Medicine; Glucocorticoids; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadi | 2011 |
[Facial angioedema following hyaluronic acid injection].
Topics: Angioedema; Anti-Inflammatory Agents; Dermatologic Agents; Drug Eruptions; Drug Therapy, Combination | 2012 |
[The result of neglected or erroneous treatment. Mentally handicapped by hay fever].
Topics: Cognition Disorders; Histamine H1 Antagonists; Humans; Loratadine; Rhinitis, Allergic, Seasonal | 2002 |
Decongestant effects of antihistamines: a class effect?
Topics: Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Loratadine; Nasal Decongestan | 2003 |
Do leukotriene receptor antagonists have a place in pharmacotherapy of allergic rhinitis?
Topics: Acetates; Administration, Intranasal; Administration, Oral; Androstadienes; Anti-Allergic Agents; Cy | 2003 |
Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.
Topics: Administration, Inhalation; Adult; Allergens; Anti-Allergic Agents; Betula; Biomarkers; Chemokines, | 2003 |
[In seasonal and perennial rhinitis. Superiority to standard H1 blockers].
Topics: Anti-Allergic Agents; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1 Antagonists; His | 2003 |
[Antihistaminics. Side effects also after raising dosage at the placebo level].
Topics: Anti-Allergic Agents; Benzimidazoles; Butyrophenones; Cetirizine; Double-Blind Method; Histamine H1 | 2003 |
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.
Topics: Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Patient Satisf | 2003 |
[Respiratory allergies in the child and the adult].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag | 2004 |
[Older antihistaminics often act as sedatives. Hay fever gone -- reaction capacity, too].
Topics: Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Placebos; Rhin | 2003 |
Nasal saline: placebo or drug?
Topics: Anti-Allergic Agents; Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; Lora | 2004 |
[Not a minor illness. Hay fever therapy should not be left to the patient].
Topics: Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Rhinitis, Alle | 2004 |
[Combination therapy of allergic rhinitis. So that from hay fever asthma won't come].
Topics: Anti-Allergic Agents; Asthma; Child; Drug Therapy, Combination; Glucocorticoids; Histamine H1 Antago | 2004 |
Desloratadine partially inhibits the augmented bacterial responses in the sinuses of allergic and infected mice.
Topics: Animals; Antigens, CD; Cells, Cultured; Colony Count, Microbial; Female; Flow Cytometry; Histamine H | 2004 |
[Nasal obstruction on the decline. Antihistamine allows allergic patients to breathe].
Topics: Cholinergic Antagonists; Clinical Trials as Topic; Histamine H1 Antagonists, Non-Sedating; Humans; L | 2004 |
Treatment of ear pain in pilots in flight.
Topics: Aerospace Medicine; Anti-Allergic Agents; Humans; Loratadine; Pain; Rhinitis, Allergic, Seasonal; St | 2005 |
Sexual dysfunction in patients with allergic rhinoconjunctivitis.
Topics: Adult; Coitus; Conjunctivitis, Allergic; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Lib | 2005 |
Diphenhydramine vs desloratadine comparisons must consider risk-benefit ratio.
Topics: Cognition Disorders; Diphenhydramine; Histamine H1 Antagonists; Histamine H1 Antagonists, Non-Sedati | 2006 |
Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis.
Topics: Acetates; Administration, Intranasal; Administration, Oral; Adolescent; Adult; Anti-Allergic Agents; | 2008 |
[The influence of desloratadine on course of intermittens allergic rhinitis].
Topics: Adolescent; Adult; Child; Child, Preschool; Conjunctivitis, Allergic; Disease Progression; Female; H | 2005 |
Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine.
Topics: Basophils; Calcimycin; Concanavalin A; Histamine H1 Antagonists; Histamine Release; Humans; Immunogl | 1994 |
Loratadine--a new antihistamine.
Topics: Drug Interactions; Humans; Loratadine; Rhinitis, Allergic, Seasonal | 1993 |
[Claritin in the combined therapy of bronchial asthma].
Topics: Anti-Asthmatic Agents; Asthma; Drug Evaluation; Histamine H1 Antagonists; Humans; Loratadine; Remiss | 1997 |
The clinical efficacy of H1 antagonists in urticaria and rhinitis.
Topics: Anti-Allergic Agents; Cetirizine; Histamine H1 Antagonists; Humans; Loratadine; Mathematical Computi | 1998 |
The best therapy for allergic rhinitis.
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Drug Combinations; Fluticasone; Hu | 1998 |
Rhinitis management: the patient's perspective.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Conjunctivitis, Allergic; Humans; Loratadine; Pa | 1998 |
Same drug, different outcomes in the environmental exposure unit.
Topics: Anti-Allergic Agents; Cetirizine; Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Hum | 1999 |
[Evaluation of loretadine therapy by rhino-manometry in patients with allergic rhinitis].
Topics: Adolescent; Age Factors; Anti-Allergic Agents; Child; Female; Humans; Loratadine; Male; Manometry; N | 1999 |
Desloratadine: A new, nonsedating, oral antihistamine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Drug Interactions; Histamine H1 Antagonist | 2001 |
Newer antihistamines.
Topics: Administration, Oral; Anti-Allergic Agents; Cetirizine; Chlorpheniramine; Conscious Sedation; Diphen | 2001 |
[A new antihistamine. Inhibiting inflammation in rhinorrhea and nasal congestion].
Topics: Cholinergic Antagonists; Histamine Release; Humans; Loratadine; Rhinitis, Allergic, Seasonal | 2001 |
[Seasonal allergic rhinitis. Nasal obstruction can also beh improved].
Topics: Anti-Allergic Agents; Double-Blind Method; Humans; Loratadine; Multicenter Studies as Topic; Nasal O | 2001 |
Desloratadine.
Topics: Asthma; Clinical Trials as Topic; Drug Interactions; Histamine H1 Antagonists; Humans; Loratadine; R | 2001 |
[The third-generation antihistaminics. Can they prevent the tier change?].
Topics: Asthma; Bronchial Hyperreactivity; Histamine H1 Antagonists; Humans; Loratadine; Placebos; Randomize | 2002 |
Desloratadine (Clarinex).
Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Controlled Clinical Trials as Topic; Disorder | 2002 |
Which is more effective for as-needed treatment of seasonal allergy symptoms: intranasal corticosteroids or oral antihistamines?
Topics: Administration, Intranasal; Adult; Androstadienes; Evidence-Based Medicine; Female; Fluticasone; Glu | 2002 |
Loratadine, a non-sedating H1-receptor antagonist (antihistamine)
Topics: Cyproheptadine; Histamine Antagonists; Histamine H1 Antagonists; Humans; Loratadine; Rhinitis, Aller | 1989 |